QR Pharma’s Posiphen® was shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein

QR Pharma to Present Positive Results of Posiphen® in a Clinical Mechanism of Action Study at the International Congress on Alzheimer’s Disease 2010

Massachusetts General Hospital and QR Pharma Start a Collaboration on Posiphen® and Parkinson’s Disease

QR Pharma Funding

QR Pharma to Present on Alzheimer’s Disease at the NeuroScienceNetwork

QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome

QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients

Paul Blake, Hal Broderson and Franz Hefti Join QR Pharma Board Company Taps Region’s Proven Experts in Growing Successful Companies

QR Pharma Receives Seed Investment from Ben Franklin Technology Partners for Further Development of Clinical Stage Compounds to Treat Alzheimer’s Disease

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease